Abstract:Abstract Background and Aims Upcoming glucocorticoid (GC)-sparing treatment strategies like avacopan could potentially diminish or replace the need of GC therapy for ANCA-associated-vasculitis (AAV) in the future. Therefore, a proper assessment of GC-related morbidity in AAV is required to provide further justification of such therapies. The aim of this study was therefore to assess the incidence of common toxicities and to further investigate the effect of GC-treatment on the incidence and management of diabetes mellitus, arterial hypertension and hypercholesterolemia. Method In this single-centre-cohort-study we screened medical records for patients with a diagnosis of AAV admitted to the Robert-Bosch-hospital (RBK) in Stuttgart, Germany on a regular basis. We assessed the dosage and duration of immunosuppressive therapy used to treat AAV, as well as the incidence and therapies of arterial hypertension, diabetes mellitus and hypercholesterolemia. For this study, we observed the vasculitis time course during the acute phase (180 days) after either the initial diagnosis or relapse for each patient. Results We included 74 patients admitted to the RBK since 2004 up to the current date. Most common subtype of AAV was GPA (n = 48 patients), followed by MPA (n = 22) and EGPA (n = 4). Including relapses, a total of 127 events were observed. We followed patients for a mean time of 8 years (SD 3.9, 0.9 - 18.0 years). Mean duration of glucocorticoid therapy in total was 4.2 years (SD 3.6, 0.3-14.7 years). All of the patients received prednisolone, whereas 73% of the patients furthermore were administered methylprednisolone for induction therapy. Overall, 34% of the patients were diagnosed with diabetes before or after the diagnosis of AAV (14% pre-existing diabetes, 20% new-onset diabetes). Daily and accumulated GC-dose did not differ between patients with or without diabetes. However, there was a significant higher accumulated GC dose in patients requiring insulin-therapy for diabetes management in comparison to those with oral antidiabetics (p-value = 0.0214). 89% of the patients were treated with antihypertensive therapy (38% pre-exisiting hypertension, 51% new-onset hypertension). We found that the accumulated dose of prednisolone within the first 180 days after a vasculitis event was not significantly higher for patients with documented hypertension. However, we detected that the mean accumulated GC dose after a vasculitis event was significantly higher for the subgroup of patients in whom an escalation of antihypertensive therapy was initiated in comparison to the patients whose therapy was stable or even deescalated (p-value = 0.0001). With regard to hypercholesterolaemia, there was no statistical difference in the accumulated GC-dose during the acute course between patients requiring statin-therapy and those who did not. Conclusion GC related toxicities are common in patients with AAV. This study provides additional evidence about the incidence of treatment related harms in AAV to further promote importance of alternative reduced dose or even GC free treatment approaches. This may be relevant in detecting risk groups for whom upcoming GC-sparing treatment strategies such as avacopan are essential to reduce treatment-related harm.

Avacopan as an add-on therapy for ANCA-associated vasculitis: a pharmacological overview

Avacopan in the treatment of ANCA-associated vasculitis

Avacopan for the treatment of ANCA-associated vasculitis: an update

Complement Inhibition in ANCA-Associated Vasculitis

Avacopan for anti-neutrophil cytoplasm antibodies-associated vasculitis: a multicentre real-world study

Role of Avacopan on Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

The complement system and its role in the treatment of ANCA-associated vasculitis

Superiority of Avacopan and Mepolizumab to Glucocorticoid Tapering in the Treatment of Anti-neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Systematic Review

Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage

The real-world use and effectiveness of avacopan in routine practice for the treatment of ANCA vasculitis. First experiences in Spain

Update on targeted treatments for ANCA-associated vasculitis

ANCA-associated vasculitis—treatment standard

Avacopan in the treatment of refractory scleritis secondary to granulomatosis with polyangiitis: A case report

Effectiveness and Safety of Avacopan as a Combination Therapy with Glucocorticoids or Monotherapy in Patients with Microscopic Polyangiitis

[Management of ANCA-associated vasculitides]

Safety and Efficacy of Avacopan in Patients with C3 Glomerulopathy: Randomized, Double-Blind Clinical Trial

Effect of Mild or Moderate Hepatic Impairment on the Pharmacokinetics of Avacopan, a Small‐Molecule Complement C5a Receptor Antagonist, for the Treatment of Antineutrophil Cytoplasmic Autoantibody‐Associated Vasculitis

Is There a Place for Complement Inhibition with Monoclonal Anti-C5a Antibody Vilobelimab in the Treatment of Patients with ANCA-associated Vasculitis?

ANCA-associated Vasculitides--advances in Pathogenesis and Treatment.

ANCA Associated Vasculitis: the Journey to Complement-Targeted Therapies

#4732 GLUCOCORTICOID-RELATED ADVERSE EFFECTS IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS